CLNN · Clene Inc. · Insider Trading

This option was granted on October 20, 2026 as an option for 20,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.73 per share. The options vest in 12 equal monthly installments on the 20th day of each calendar month, beginning November 20, 2026, until such shares are fully vested.

This option was granted on October 20, 2026 as an option for 55,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.73 per share. The options vest in 12 equal monthly installments on the 20th day of each calendar month, beginning November 20, 2026, until such shares are fully vested.

This option was granted on October 20, 2026 as an option for 30,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.73 per share. The options vest in 12 equal monthly installments on the 20th day of each calendar month, beginning November 20, 2026, until such shares are fully vested.

Kensington Clene 2021, LLC purchased 198,171 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended.

The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The securities owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all securities owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

Mr. Matlin purchased 434,451 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended.

Mr. Etherington purchased 15,244 shares of common stock of Clene Inc. for a purchase price of $3.28 per share in a registered direct offering directly from the Issuer. The issuance of such securities was approved by the Issuer's board of directors in accordance with Rule 16 (b)-3 of the Securities Exchange Act of 1934, as amended.

This option was granted on August 13, 2026 as an option for 6,230 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 3,514 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 4,752 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 4,872 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 3,674 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 3,514 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 3,794 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

This option was granted on August 13, 2026 as an option for 3,195 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.

The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred.

The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received.

Currently exercisable

The Reporting Person was deemed to beneficially own the Warrants reported herein indirectly through SymBiosis II, LLC (the "Fund") by virtue of the Reporting Person's role as Managing Partner of the Fund and the resulting voting and investment power over the Fund's holdings. Effective July 17, 2026, management of the Fund's investment portfolio was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to have voting or investment power over the securities held by the Fund, including the Warrants. Accordingly, the Reporting Person no longer beneficially owns the Warrants reported herein. No consideration was paid or received in connection with this change, and no Warrants were exercised, sold, or transferred.

The Reporting Person was deemed to beneficially own the Warrants indirectly through SymBiosis II LLC by virtue of voting and investment power over the Fund's holdings. Effective July 17, 2026, such power was transferred to a different, unaffiliated third party manager, and the Reporting Person ceased to beneficially own the Warrants reported herein. No consideration was paid or received.

Currently exercisable

This option was granted on June 11, 2026 as an option for 15,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested.

This option was granted on June 11, 2026 as an option for 45,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested.

This option was granted on June 11, 2026 as an option for 65,000 shares of Common Stock under the Clene Inc Amended 2020 Stock Plan at an exercise price of $5.53 per share. The options vest with respect to the first 25% of such shares on June 11, 2027 and then in 36 equal installments of the balance of the shares of Common Stock on the 11th day of each month beginning July 11, 2027 until such share are fully vested.

This option was granted on May 21, 2026 as an option for 3,659 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 2,228 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 2,158 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 2,791 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 2,861 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.

This option was granted on May 21, 2026 as an option for 2,064 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 2,064 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 1,876 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant.

This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested.